From GlobeNewswire: 2025-06-19 02:00:00

Transgene announced 100% Disease-Free Survival in Phase I trial with TG4050 for head and neck cancer. Phase II randomization expected by end of 2025, with first immunogenicity data in H2 2026 and preliminary efficacy data in H2 2027. TG4050 is an individualized neoantigen therapeutic vaccine based on Transgene’s myvac platform. The Phase I trial showed sustained T cell responses and met all endpoints for safety and disease-free survival. The successful completion of Phase II screening ahead of schedule demonstrates the platform’s potential in treating solid tumors. Transgene is preparing for a new Phase I trial in a second indication in Q4 2025.



Read more at GlobeNewswire: Transgene Completes Initial Patient Screening in Phase II